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Abstract 
Aims: Although a previous study found high risk of breast cancer in mothers of children with soft tissue sarcomas, breast cancer risks in 
mothers of sufferers of other childhood cancers largely remain unknown. The aetiology is not fully understood. The present study 
explored this excess by varying type of childhood solid cancer and formulated a hypothesis. 
Methods: Mothers of 2668 children with solid tumours included in the Manchester Children's Tumour Registry, 1954–96, were traced 
and followed up to 31 December 2000 through the UK National Health Service Central Register. Standardized incidence ratio (SIR), p-
values and 95% confidence intervals were calculated from age and calendar-year-specific female breast cancer incidence rates for 
England and Wales. 
Results: There was a significant excess of breast cancer in mothers overall (SIR=1.3, 95%CI=1.0–1.5) mainly due to mothers of children 
with rhabdomyosarcoma (RMS) (SIR=2.2, 95%CI=1.0–4.0), skin cancer (SIR=7.9, 95%CI=2.9–17.1) and central nervous system 
tumours (SIR=1.2, 95%CI=0.9–1.8). Maternal breast cancer risk was associated with late age at birth of the index child, and male sex 
and young age at diagnosis in the index child. Risk was highest in the ten years, following the birth of the index. The pattern was seen 
most strongly in mothers of children with embryonal RMS. 
Conclusion: There are excesses of breast cancer in mothers of children with solid tumours in general and specifically in RMS, skin and 
central nervous system (CNS). There appears to be a temporal relationship between certain tumours in children and breast cancer in 
their mothers, suggesting an origin of their respective pregnancy. We propose a mother–foetal interaction mechanism to explain this 
association. 
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Introduction 
Since a twofold increased risk of breast cancers among first 
degree relatives of children with soft tissue sarcomas was 
reported [1, 2], it has been found that there is an increased 
breast cancer risk among the mothers of children with solid 
tumours in general [3] and specifically with soft tissue sarcoma 
[4,5]. The breast cancer risks of mothers in other solid tumours 
have not been explored. A possible mechanism largely remain 
unknown although it is known that germline mutations in certain 
cancer-associated genes, such as the TP53 or BRCA2 gene, 
predispose to the development of both specific childhood 
cancers, for example sarcomas or CNS and adult breast cancer 
[6–10]. The purpose of the present study was to investigate this 
excess by analysing risks of maternal breast cancer associated 
with various types of solid tumour. We also sought to describe 
this association by characteristics in children and mothers and 
attempted to formulate a hypothesis to explain the pattern of 
breast cancer risk observed in the mothers. 
 
Materials and methods 
Study subjects 
The mothers of 2668 children with histologically confirmed solid 
tumours diagnosed younger than 15 years of age, who were 
included in the Manchester Children's Tumour Registry (MCTR) 
between 1 January 1954 and 31 December 1996 were eligible. 
The ascertainment procedure and the follow-up procedure have 
been described in detail elsewhere [3]. A summary is provided 
below. Following approval from the appropriate research ethics 
committees, mothers of the index children were traced and 
followed up to 31 December 2000 through the UK National 
Health Service Central Register (NHSCR), providing continuous 
notification of details of cancer registrations and causes of 
death (flagging). Diagnosis of carcinoma of the breast was 
coded according to the contemporaneous revision of the 
International Classification of Diseases for Oncology [11, 12] 
and the International Classification of Diseases. All diagnoses in 
children were coded according to International Classification of 
Diseases for Oncology Second Edition and regrouped into a 
smaller number of diagnostic categories according to the Birch 
and Kelsey (BK) classification scheme, which groups 
biologically similar tumours together [13]. All cases were 
categorized on the basis of morphology and topography codes 
into broad groupings as follows: Hodgkin disease (HD), non-
Hodgkin lymphoma (NHL), central nervous system (CNS) 
tumours, which included benign and borderline tumours, 
retinoblastoma (RB), neuroblastoma, peripheral primitive 
neuroectodermal tumours (PPNET), Wilms tumour (WT), 
hepatoblastoma (HB), osteosarcoma  and chondrosarcoma 
(Osteo & Chondro), rhabdomyosarcoma (RMS), other bone and 
soft tissue (ST) sarcoma, gonadal germ cell tumours (GCT), 
non-gonadal GCT, adrenocortical carcinoma (ACC), malignant 
neoplasms of skin (melanoma and non-melanoma), carcinoma 
(excluding of skin), other rare specified tumours, and 
unspecified neoplasms. The morphology and topography code 
allocations defining BK groups and algorithms for selecting the 
groups are available upon request. 
Statistical methods 
Expected numbers of breast cancers were calculated from 
serial age-specific female breast cancer incidence for England 
and Wales, from 1971 onwards, applied to the similarly defined 
arrays of person-years at risk generated by the data. National 
rates were used rather than north-west England regional rates 
to allow for migration of families out of the region during the 
lengthy follow-up period. All population data were supplied by 
the Office for National Statistics, London, UK. For earlier years 
at risk, the incidence rates for 1971 were used to calculate 
expected numbers. To calculate the risk of carcinoma of the 
breast, mothers entered the person-years at risk on the date of 
birth in the index child and left the person-years at risk on the 
date of diagnosis of carcinoma of the breast, date last known to 
be alive, date of embarkation from the UK, date of death, or the 
closing date of the study, whichever was the earlier. Two-sided 
p-values and 95% confidence intervals (CI) of standardized 
incidence ratios (SIRs) were computed on the assumption the 
observed numbers followed a Poisson distribution. All analyses 
have been carried out using Stata [14]. 
Separate analyses were initially performed for groups of 
mothers defined by diagnostic group in the index child. In those 
groups, showing a statistically (or marginally) significantly 
elevated SIR, the excesses were explored in more detail by 
comparing sub-groups defined by characteristics in the children 
and their mothers according to the following rationale. Germline 
mutations may lead to earlier ages of cancer onset. We 
hypothesized that early age of diagnosis in the index child may 
be a marker for breast cancer risk in the mothers. We therefore 
analysed breast cancer risks in selected sub-groups of mothers 
whose children were below the population median age for 
diagnosis of their respective tumours. Similarly, we conducted 
analyses of breast cancers by age at diagnosis in the mothers. 
Factors that may indicate mother–foetal interaction in 
pregnancy include differences in breast cancer risks in mothers 



















Table 1: Standardized incidence ratios in mothers by diagnostic groups in children 
of boys compared with girls [5] and a temporal relationship 
between birth of the index child and onset of breast cancer in 
the mother. To investigate this possibility, we performed 
separate analyses in mothers of boys and mothers of girls and 
estimated breast cancer risks by time elapsed since the birth of 
the index child (<10 years and ≥10 years). To examine the 
effect of maternal age at the birth of the index, we also 
performed separate analyses for maternal age groups (<35 
years and ≥35 years). 
 
Results 
The mothers of 2345 (88%) were successfully traced and 
flagged at NHSCR. The reasons for non-trace were due to lack 
of name/date of birth, adoption, emigration, in prison and in the 
armed forces. 
Table 1 shows SIRs for breast carcinoma in mothers of children 
with solid tumours by diagnostic groups in children. As 
previously reported, overall, there was a significant excess of 
carcinoma of the breast in the mothers (O 99, SIR 1.3, p<0.05) 
[3]. For individual diagnostic groups in children, significant 
excesses were shown among mothers of children with RMS (O 
10, SIR 2.2, p<0.05), and mothers of children with malignant 
neoplasms of skin (O 6, SIR 7.9, p<0.001). An excess of 
borderline significance was found among mothers of children 
with CNS tumours (O 32, SIR 1.2, 95%CI 0.9–1.8). No group 
showed a significant deficit of breast cancer. 
There was no significant excess risk of carcinoma of the breast 
in mothers of children with osteosarcoma and chondrosarcoma.  




















Table 2: SIRs of carcinoma of the breast in mothers of children with eRMS, skin cancer and CNS tumours 
Therefore, previous findings based on an earlier series from the 
MCTR were not substantiated in this extended series [15]. 
In view of our previous findings, mothers of children with 
embryonal RMS (eRMS) were analysed separately and showed 
a significant excess of breast cancer (O 6, SIR 2.7, p<0.05). 
The following diagnostic groups were selected for sub-group 
analyses of maternal breast cancer risk: eRMS, skin cancer and 
CNS tumours (Table 2). 
For the individual diagnostic group of eRMS in the index, there 
were significant excesses of carcinoma of the breast in mothers 
of boys (O 6, SIR 4.2, p<0.01), breast cancer diagnosed under 
50 years old (O 4, SIR 4.7, p<0.05), breast cancer in the ten 
years following birth of the index (O 4, SIR 19.5, p<0.001), and 
in mothers above 35 years old at birth of the index (O 4, SIR 
12.6, p<0.001). In addition analyses by age at diagnosis in the 
index child showed that mothers of children under median age 
at diagnosis had a much higher SIR of 7.3 (O 6, p<0.001) than 
mothers of children at the median age and above (SIR=0). This 
was due to mothers of children in the first age quartile at 
diagnosis (O 5, SIR 14.4, p<0.001). For skin cancer in the index 
child, there were significant excesses among mothers in all sub-
groups. However, markedly higher SIRs were observed for 
mothers in the first ten years, following the birth of the index and 
aged 35 years or more at the birth of the index. The population 
median age at diagnosis of skin cancer is above 60 years. 
Therefore, no analyses by age of the index case were carried 
out since all index cases were exceptionally young and located 
at the extreme lower end of the age distribution. When 
melanoma and non-melanoma skin cancers were analysed 
separately, a similar pattern of results was obtained for both 
groups. For individual diagnostic group of CNS tumours in the 
index, non-significant SIRs above 1.5 were found for mothers of 
boys, mothers in the ten years following birth of the index, and 
mothers above 35 years old at birth of the index. PNET was the 
only CNS tumour sub-group with a population median age 
below 15. Analyses of breast cancer in mothers of children with 
PNET diagnosed below the median age of nine years showed O 
8, SIR 1.9 and 95%CI 0.8–3.8. 
 
Discussion 
The study indicates that the excess risk of carcinoma of the 
breast among mothers of children with solid tumours is not 
uniform across all groups, but is associated with a small number 
of tumour types and patient characteristics. 
The observed pattern is seen most strongly in eRMS. There are 
higher risks in mothers of children with eRMS diagnosed at very 
young ages, mothers of boys and in the ten years following birth 



















of the index, suggesting an origin of the respective pregnancy. 
A biologically feasible interpretation would be hormonal mother–
foetal interaction in pregnancy in genetically susceptible 
individuals [5]. 
This is suggested by higher risks of developing carcinoma of the 
breast in mothers in the first few years after birth of the index 
and higher risk in mothers of boys. It is likely that in these 
children the eRMS originates before birth. It is known that the 
foetus itself is actively involved in the production and regulation 
of oestrogen, a hormone that is an established aetiological 
factor in breast cancer. 
Risk factors for breast cancer, identified in population-based 
studies, include early menarche, late menopause, late first full-
term pregnancy, and use of exogenous oestrogens. All these 
factors increase the amount of oestrogen to which the breast 
epithelium is exposed [16]. To meet the demand for oestrogen, 
during pregnancy foetal adrenals, grow rapidly and 
disproportionately [17]. In the ten weeks between 20th and 30th 
week of pregnancy, the foetal adrenal cortex undergoes a high 
rate of cell proliferation and the size and weight of foetal 
adrenals are doubled, reaching 10–20 times the relative size of 
the adult adrenals. Enormous quantities of C19 steroid (DHEA-
S), 100–200 mg/day are produced by the foetal adrenal cortex 
for oestrogen synthesis. 
The foetal adrenal cortex also undergoes a process of 
maturation involving apoptosis (programmed cell death), a basic 
process in tissue remodelling, to eventually produce the mature 
adrenal cortex. Apoptosis starts in the 14th week, increases 
with advancing gestation and is maximal during the first 
postnatal month [18]. 
We hypothesize that a germline defect in the foetus in a gene 
involved in cell-cycle control, apoptosis and tissue development, 
results in abnormal levels of steroid hormones via aberrant 
functioning of the foetal adrenal cortex, due to failure of the 
normal process of apoptosis and maturation. 
This would explain the observed temporal relationship between 
pregnancy, birth of the index child, development of tumour in 
the child and development of breast cancer in the mother. One 
such gene is TP53. 
The differences in risks between mothers of boys and girls with 
eRMS might suggest that the relevant cancer-associated genes 
in male foetuses are more important in maintaining 
development and normal functioning of fast growing organs, 
such as the foetal adrenal cortex than in females. Male foetuses 
grow faster and males have higher average birth weight but 
shorter gestations than girls [19, 20]. 
The striking effects of maternal age at birth of the index child 
may suggest that timing of pregnancy in mothers is also 
important. In older women, there may be a greater chance that 
precancerous changes are present in the breast epithelium. In 
these circumstances, carrying a foetus with a cancer 
predisposing mutation may trigger the process of 
carcinogenesis, and thus accelerate the development of breast 
cancer, following the birth of the index child. The effect would be 
even more marked in mothers who carried the same mutation. 
A practical implication of our model is that the highest risks and 
earliest ages at onset would be seen in mothers of babies who 
were mutation carriers and who themselves also carried the 
mutation. These mothers are predisposed and are also 
subjected to abnormal exposure to steroids produced by the 
foetal adrenal cortex, which had failed to mature (apoptosis) in 
the normal way. Mothers of babies who were mutation carriers 
would also be at increased risk even though they themselves do 
not carry the mutation. We would predict that carrier mothers of 
non-carrier babies and non-parous carriers would have a later 
age of onset (though still young) than carrier mothers of carrier 
babies. 
In this series of eRMS, there was one known case with a 
germline TP53 mutation, whose mother was also a mutation 
carrier. In addition, this case had a sister, 15 months older, who 
carried the mutation. The mother's breast cancer was 
diagnosed at age 27 years, 19 months after the birth of the 
child. Four children with other tumours, ACC, astrocytoma and 
PNET (2 cases) carried germline TP53 mutations. Their 
mothers, who were also confirmed mutation carriers, all 
developed breast cancer seven years or less after the birth of 
the respective children.  
The striking excesses of breast cancer in mothers of children 
with eRMS in the ten years following birth of the index are 
unlikely to be completely explained by a transient increase in 
risk of breast cancer following the first pregnancy in mothers. 
First pregnancy has been reported to be associated with 
increased risk of breast cancer in the 15 years or less after birth 
[21, 22]. However, the risk of breast cancer in the five years 
after the first birth is only just above 1 (RR=1.1) compared with 
nulliparous women [22]. Although highest transient increases in 
risk of breast cancer have been found in mothers with family 
history of breast cancer (RR=1.5, 95% CI 0.9–2.4) [22] and 
mothers above 35 years old (1.26, 95% CI 1.10–1.44) [21], the 
relative risks were no more than 2. For mothers of children with 
eRMS, the SIR was 19.5 in the ten years following the birth of 
the index child. Data on age at first birth in mothers of children 
with RMS are available since these were collected as part of 



















more general family studies. These allow us to derive years 
since the birth of the first child. We carried out further analyses 
adjusting for maternal age at first birth (under 35 years and 35 
years and above) and years since the first birth (below 15 years 
and 15 years and above) among the mothers, using Poisson 
regression, incorporating population breast cancer incidence 
rates [23]. The adjusted SIR is 14.7, 95% CI 4.0–54. 
The observed breast cancer excess is not explained by these 
potential confounders relevant to the first birth. The results need 
not be seen as contradictory to the previous findings of transient 
increase in risks of breast cancer in the first pregnancy since 
the present study shows that the pregnancy is a crucial period 
in the development of breast cancer in women. However for the 
mothers in the present study, the pregnancy with the child who 
subsequently develops cancer appears to be of greater 
importance in the development of breast cancer than that with 
the first child and the striking effects in the mothers observed in 
the present study might reflect a different aetiology from 
mothers of children without cancer. The mechanism proposed 
above, which relates breast cancer risk to peculiarities of 
adrenal cortex development, might explain the marked excess. 
Because of the nature of this cancer-registry-based study, 
retrospective direct measurement of oestrogen levels in 
pregnancy with the index is not possible. Similarly, access to 
birth records which may contain other relevant details would 
require individual written consent, which would be impractical 
since the births date back to 1939 and many index patients and 
their mothers have died. Furthermore, it is likely that many 
records will have been destroyed. However, data on birth weight 
are available for children with RMS as part of previous family 
studies. Oestrogens are known to stimulate cell proliferation and 
represent an important determinant of foetal growth [24]. 
Birthweight has been used as a surrogate measure for steroid 
hormone exposure during pregnancy, and a positive correlation 
between steroid hormone concentrations and birthweights has 
been observed [25]. 
We compared the birthweights of the children with RMS whose 
mothers developed breast cancer, and index children whose 
mothers did not, with that of live-born children in the general 
population. Mean birthweights of index children of mothers with 
breast cancer and mothers without are 257 and 54 g more than 
that of the general population, respectively, (with breast 
cancer=3600 g, without breast cancer=3397 g, population=3343 
g). Mean birthweights of boys with RMS whose mothers did or 
did not develop breast cancer are 114 and 27g more than that 
of male babies in the general population, respectively. Mean 
birthweights of girls with RMS whose mothers did or did not 
develop breast cancer are 658 and 75 g more than that in the 
general population, respectively. There is a trend of decreasing 
birthweight among index cases whose mothers had breast 
cancer, index cases whose mothers did not have breast cancer 
and children in the population. This is consistent with the role of 
oestrogen in foetal development, and with our hypothesis 
relating to failure of normal maturation of the foetal adrenal 
cortex. 
Interestingly, the present study reported an excess of carcinoma 
of the breast in mothers of children with skin cancer (melanoma 
and non-melanoma combined) with the highest excess in the 
first ten years, following birth of the index (SIR 23.5). Skin 
cancer is typically an adult-onset cancer and is very rare in 
children. The median age for sporadic melanoma is 67 and 35 
years for familial melanoma. Therefore, all childhood cases are 
unusual and may be associated with genetic susceptibility. It is 
known that germline mutations in CDKN2A are the most 
common cause of inherited susceptibility to melanoma. 
CDKN2A encodes two proteins via alternate reading frames 
(ARFs). The p14ARF product, acting via the p53 pathway, can 
induce cell-cycle arrest or apoptosis. In multi-case melanoma 
families with mutations affecting p14ARF specifically there 
appears to be increased risk of breast cancer [26]. This is 
consistent with the mechanism proposed above and might 
explain the pattern of development of breast cancer in their 
mothers. 
In mothers of children with CNS tumours, the present study 
showed borderline significant excesses among mothers of boys 
and mothers diagnosed in the ten years following the birth of the 
index. This might suggest roles of BRCA2 as well as TP53. 
Biallelic BRCA2 germline mutation carriers do develop 
childhood brain cancers as recently reported [6, 10], although 
BRCA2 heterozygotes do not [27]. This could be an explanation 
for the combination of breast cancer in a mother and brain 
tumour in her child. It has been reported that loss of BRCA gene 
function activates a p53-dependent cellular response [28], 
suggesting mutation in p53 may be required before inactivation 
of BRCA2 may lead to the development of breast cancer. 
In contrast to an earlier study [15], we did not find a statistically 
significant increase in breast cancer risk in mothers of children 
with osteosarcoma and chondrosarcoma (SIR 1, 95%CI 0.6, 
3.2). The SIR for breast cancer in mothers of children with 
retinoblastoma was of a similar magnitude (SIR 1.7, 95% CI 0.6, 
4.0). We considered the possibility that there may be an excess 
risk of breast cancer in mothers in both groups, during early 
years of follow-up, mediated by mutations in the RB1 gene. 
However, only one mother in both groups combined was 



















diagnosed with breast cancer in the first ten years, following the 
diagnosis in her child. 
Considering childhood cancers are rare events, the sample size 
in our study is relatively large and allows us to carry out 
stratified statistical analyses. However, non-statistically 
significant results in certain diagnostic groups in children cannot 
completely rule out the possibility of increased breast cancer 
risk due to the aforementioned mechanism. Among other 
diagnostic groups, the highest point estimate of SIR for breast 
cancer is in mothers of children with adrenocortical carcinoma 
(ACC) although statistically not significant due to the small 
number. Of 12 mothers of children with ACC, two mothers 
developed breast cancer following birth of the child, compared 
with an expected number of 0.3. It is thought that ACC 
originates in the foetal adrenal cortex, that is an abnormality in 
the process of cell proliferation and programmed cell death 
during adrenal development. Furthermore, germline mutations 
in TP53 have been found among the majority of ACC cases in a 
number of studies [29, 30]. 
In this population-based study, a near complete ascertainment 
of children with solid tumours in a well-defined geographical 
area was achieved, and the case children included in the study 
were representative of all the case children in the corresponding 
population series. Therefore, the present study is unlikely to be 
subject to ascertainment bias due to notification of severely 
affected families or the knowledge of family history of cancer in 
surviving cases only. Neither can the excesses be explained by 
the bias due to the follow-up procedure, because the majority of 
mothers were successfully traced and there are no reasons to 
believe that the causes of non-trace are influenced by 
occurrence of breast cancer. 
The study is free of reporting bias because all data were 
obtained from population registries rather than self-reports, that 
is both breast cancer in mothers and childhood cancers were 
derived from population-based data. However, another possible 
bias worth mentioning is the 'healthy mother effect', by analogy 
with the healthy worker effect, that is mothers may experience a 
lower breast cancer risk than those non-parous women in the 
general population. 
Childbearing has been demonstrated to be associated with 
decreased breast cancer risk in human and animal studies due, 
in part, to the pregnancy-specific hormone, chorionic 
gonadotropin (hCG) [31]. The confounding effect due to 
childbearing in mothers in the study population, is not negligible 
because childless women up to 40 years old in the reference 
population used to estimate expected numbers represent about
20%; therefore, true SIRs would be expected to be higher than 
those reported here. Furthermore, there was a slightly 
increasing trend of breast cancer incidence in the general 
population since 1971. The use of the 1971 rates to calculate 
expected number of breast cancers before 1971 would 
overestimate the expected numbers. In addition, use of national 
rates rather than regional would also tend to overestimate the 
expected numbers of cases since rates tend to be a little higher 
in the south of England than in the north. Thus, the 
standardized registration ratio for breast cancer in the north-
west in 2000 was 98% compared with 109% in the south-west 
[32]. The SIRs reported here are therefore conservative 
estimates of true SIRs. 
 
Conclusion 
In conclusion, the study confirms and extends the previous 
findings of a temporal relationship between embryonal RMS in 
children and breast cancer in their mothers. We propose a 
hypothesis to explain these observations and suggest a 
possible mechanism. This mechanism may also be operating in 
mothers of children with other types of cancers. The present 
study points to pregnancy as the critical period, when mothers 
and children are physiologically linked. Germline mutations to 
cancer-associated genes, inherited or de novo might play an 
important role. Germline mutations might commonly target the 
p53 pathway affecting tissue remodelling in the foetal adrenal 
cortex, not just a single gene within that pathway. The pathway 
may be disrupted by a germline mutation within the TP53 gene 
itself, as well as p14ARF, BRCA1 and BRCA2, etc. Further 
studies of aetiology of breast cancer in mothers of children with 
cancer incorporating genetic/molecular measurements including 
mutation screening of cancer-associated genes will be useful in 
exploring this hypothesis. This is feasible as tissue banks and 
appropriate genetic techniques become available. The study 
may help to define periods of highest risk to enable health 
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